Search

Your search keyword '"Hyperkalemia -- Care and treatment"' showing total 7 results
Start Over Descriptor "Hyperkalemia -- Care and treatment" Journal globenewswire
7 results on '"Hyperkalemia -- Care and treatment"'

1. Relypsa Announces European Approval of Veltassa(R) to Treat Adult Patients with Hyperkalemia (Elevated Blood Potassium Levels)

Subjects
Heart failure -- Care and treatment, Drug approval, Pharmaceutical industry, Hyperkalemia -- Care and treatment, Chronic kidney failure -- Care and treatment, Banking, finance and accounting industries, Business, European Union. European Commission, Veltassa (Medication)
Abstract

REDWOOD CITY, Jul 21, 2017 (GLOBE NEWSWIRE via COMTEX) -- -- Today's European Commission approval is the second worldwide; in the U.S., more than 33,000 patients have been treated with [...]

Published
2017

2. Relypsa Announces Phase 4 Study Shows Veltassa(R) Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia

Subjects
Lithium compounds, Hyperkalemia -- Care and treatment, Oral drugs, Banking, finance and accounting industries, Business, Veltassa (Medication)
Abstract

REDWOOD CITY, Calif., Aug 30, 2016 (GLOBE NEWSWIRE via COMTEX) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the Phase 4 TOURMALINE study, which compared the efficacy and [...]

Published
2016

4. European Journal of Heart Failure Publishes Pre-Specified Sub-Group Analysis of Heart Failure Patients With Hyperkalemia From Phase 3 Trial of Patiromer FOS

Subjects
Heart failure -- Care and treatment, Clinical trials, Angiotensins, Cardiac patients -- Care and treatment, Hyperkalemia -- Care and treatment, Oral drugs -- Product development, Chronic kidney failure -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, Calif., Oct 13, 2015 (GLOBE NEWSWIRE via COMTEX) -- -- Pre-specified sub-group analysis from OPAL-HK trial of hyperkalemic chronic kidney disease (CKD) patients with heart failure receiving renin [...]

Published
2015

5. Relypsa Announces FDA Acceptance of New Drug Application for Patiromer for Oral Suspension to Treat Hyperkalemia

Subjects
United States. Food and Drug Administration, Drugs -- Prescribing, Hyperkalemia -- Care and treatment, Oral medication, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, Calif., Dec 15, 2014 (GLOBE NEWSWIRE via COMTEX) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New [...]

Published
2014

6. ZS Pharma Announces Publication of Results From Phase 3 Study of ZS-9 in Patients With Hyperkalemia in the New England Journal of Medicine

Subjects
Clinical trials, Liver diseases -- Care and treatment, Hyperkalemia -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

COPPELL, Texas, Nov 21, 2014 (GLOBE NEWSWIRE via COMTEX) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the publication [...]

Published
2014

7. ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients With Hyperkalemia

Subjects
Medical research, Medicine, Experimental, Clinical trials, Liver diseases -- Care and treatment, Hyperkalemia -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

COPPELL, Texas, Jul 14, 2014 (GLOBE NEWSWIRE via COMTEX) -- ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has [...]

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results